[New antibiotics - standstill or progress]

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Antibiotic resistance is a growing global health crisis.
• A significant gap exists between the rise of resistant pathogens and the development of new antimicrobial drugs.
• The pipeline for novel antibiotics has been stagnant for over a decade.

Purpose of the Study:

• To review and present six recently developed antibiotics.
• To highlight their potential efficacy against resistant bacterial strains.
• To discuss their role in managing the increasing threat of antimicrobial resistance.

Main Methods:

• Review of existing literature and expert opinions on new antibiotic agents.
• Analysis of the spectrum of activity and target pathogens for each new drug.
• Assessment of the potential impact on antibiotic selection pressure.

Main Results:

• Ceftaroline and ceftobiprole (5th gen cephalosporins) show high activity against Methicillin-resistant Staphylococcus aureus (MRSA).
• Solithromycin (fluoroketolide) is effective against macrolide-resistant pathogens.
• Tedizolid (oxazolidinone) targets linezolid-resistant MRSA.
• Ceftolozane/tazobactam and ceftazidime/avibactam offer broad-spectrum activity against Gram-negative pathogens, including those with extended-spectrum beta-lactamases (ESBLs).

Conclusions:

• The introduction of these six new antibiotics provides vital options for treating infections caused by resistant bacteria.
• These agents can help alleviate the selection pressure on commonly used antibiotics, particularly carbapenems.
• Continued focus on novel antibiotic development is essential to address the alarming rise of resistant Gram-negative pathogens worldwide.